

Noriomi Matsumura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556053/publications.pdf>

Version: 2024-02-01

85
papers

3,540
citations

201385

27
h-index

149479

56
g-index

94
all docs

94
docs citations

94
times ranked

5905
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 5034-5045.	0.4	439
2	Dual Faces of IFN γ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2016, 22, 2329-2334.	3.2	309
3	Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 587-599.	3.2	213
4	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. <i>Nature Communications</i> , 2018, 9, 1685.	5.8	211
5	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. <i>Clinical Cancer Research</i> , 2013, 19, 1363-1374.	3.2	196
6	Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	164
7	Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. <i>International Journal of Clinical Oncology</i> , 2009, 14, 383-391.	1.0	139
8	Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138
9	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. <i>Scientific Reports</i> , 2020, 10, 2757.	1.6	134
10	VISTA expressed in tumour cells regulates T cell function. <i>British Journal of Cancer</i> , 2019, 120, 115-127.	2.9	133
11	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. <i>American Journal of Pathology</i> , 2017, 187, 2246-2258.	1.9	104
12	Subtypes of Ovarian Cancer and Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 12.	1.3	80
13	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016, 186, 1103-1113.	1.9	71
14	The activated transforming growth factor- β signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. <i>International Journal of Cancer</i> , 2012, 130, 20-28.	2.3	62
15	Oncogenic Property of Acrogranin in Human Uterine Leiomyosarcoma: Direct Evidence of Genetic Contribution in In vivo Tumorigenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1402-1411.	3.2	61
16	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. <i>British Journal of Cancer</i> , 2020, 122, 778-788.	2.9	61
17	Hepatocyte nuclear factor- β (HNF- β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 35-49.	1.3	57
18	B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49

#	ARTICLE	IF	CITATIONS
19	Association between preterm delivery and bacterial vaginosis with or without treatment. <i>Scientific Reports</i> , 2019, 9, 509.	1.6	48
20	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
21	Activated Local Immunity by CCL19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian Cancer. <i>Stem Cells</i> , 2009, 28, N/A-N/A.	1.4	42
22	Changes in the Serum Levels of Human Chorionic Gonadotropin and the Pulsatility Index of Uterine Arteries during Conservative Management of Retained Adherent Placenta. <i>Journal of Obstetrics and Gynaecology Research</i> , 2000, 26, 81-87.	0.6	39
23	Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. <i>Cancer Letters</i> , 2011, 310, 129-133.	3.2	37
24	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016, 141, 49-56.	0.6	33
25	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. <i>Cancer Science</i> , 2010, 101, 2658-2663.	1.7	32
26	Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. <i>Cancers</i> , 2020, 12, 1676.	1.7	32
27	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. <i>Oncotarget</i> , 2017, 8, 106866-106875.	0.8	30
28	Subendometrial enhancement and peritumoral enhancement for assessing endometrial cancer on dynamic contrast enhanced MR imaging. <i>European Journal of Radiology</i> , 2015, 84, 581-589.	1.2	28
29	Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts. <i>International Journal of Clinical Oncology</i> , 2020, 25, 51-58.	1.0	28
30	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. <i>Gynecologic Oncology</i> , 2020, 156, 415-422.	0.6	28
31	Suppression of <i>ABHD2</i> , identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 47620-47636.	0.8	28
32	Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma Using Magnetic Resonance Images: A Literature Review. <i>Healthcare (Switzerland)</i> , 2019, 7, 158.	1.0	26
33	The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e49.	1.0	26
34	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. <i>Medical Molecular Morphology</i> , 2019, 52, 52-59.	0.4	25
35	Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 54758-54770.	0.8	25
36	Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 868-875.	0.5	24

#	ARTICLE	IF	CITATIONS
37	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	1.0	20
38	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2022, , .	1.5	18
39	Placental Sonic Hedgehog Pathway Regulates Fetal Growth via the IGF Axis in Preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4239-4252.	1.8	17
40	The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). <i>Gynecologic Oncology</i> , 2019, 153, 312-319.	0.6	17
41	PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4627-4640.	1.7	15
42	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. <i>Cancer Biology and Therapy</i> , 2014, 15, 22-25.	1.5	14
43	Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. <i>BMC Cancer</i> , 2017, 17, 580.	1.1	14
44	The roles and limitations of bevacizumab in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1120-1126.	1.0	14
45	Impaired Wnt5a signaling in extravillous trophoblasts: Relevance to poor placentation in early gestation and subsequent preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 13, 225-234.	0.6	13
46	Epigenetic and genetic dispositions of ovarian carcinomas. <i>Oncoscience</i> , 2014, 1, 574-579.	0.9	13
47	Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e31.	1.0	12
48	Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study. <i>Hypertension Research</i> , 2022, 45, 135-145.	1.5	12
49	The effect of the type of dietary protein on the development of ovarian cancer. <i>Oncotarget</i> , 2018, 9, 23987-23999.	0.8	11
50	Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 14215.	1.6	11
51	Superparamagnetic iron oxide as a tracer for sentinel lymph node detection in uterine cancer: a pilot study. <i>Scientific Reports</i> , 2020, 10, 7945.	1.6	11
52	Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e57.	1.0	10
53	Clinical Efficacy of Ovarian Cancer Screening. <i>Journal of Cancer</i> , 2016, 7, 1311-1316.	1.2	9
54	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e247-e257.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2021, 5, 1270-1280.	1.5	9
56	Longitudinal changes in magnetic resonance imaging of malignant and borderline tumors associated with ovarian endometriotic cyst comparing with endometriotic cysts without arising malignancy. <i>European Journal of Radiology</i> , 2018, 105, 175-181.	1.2	8
57	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1001-1012.	1.0	8
58	Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. <i>International Journal of Clinical Oncology</i> , 2018, 23, 698-706.	1.0	7
59	A Novel Malignant Peritoneal Mesothelioma with <i>STRN</i> Exon 2 and <i>ALK</i> Exon 20: A Case Report and Literature Review. <i>Oncologist</i> , 2021, 26, 356-361.	1.9	7
60	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. <i>Oncology Reports</i> , 2008, 19, 505-15.	1.2	7
61	Targeting Dormant Ovarian Cancer Cells <i>In Vitro</i> and in an <i>In Vivo</i> Mouse Model of Platinum Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 85-95.	1.9	6
62	Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. <i>Journal of International Medical Research</i> , 2016, 44, 346-356.	0.4	5
63	Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 2071-2079.	2.9	5
64	Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e62.	1.0	4
65	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	4
66	Scientific evaluation of alleged findings in HPV vaccines: Molecular mimicry and mouse models of vaccine-induced disease. <i>Cancer Science</i> , 2022, 113, 3313-3320.	1.7	4
67	<i>Pneumocystis</i> Pneumonia in Non-HIV Pregnant Women Receiving Chemotherapy for Malignant Lymphoma: Two Case Reports. <i>Case Reports in Obstetrics and Gynecology</i> , 2017, 2017, 1-4.	0.2	3
68	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <i>Medical Science Monitor</i> , 2017, 23, 826-833.	0.5	3
69	Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor. <i>Healthcare (Switzerland)</i> , 2019, 7, 145.	1.0	3
70	Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images. <i>Case Reports in Obstetrics and Gynecology</i> , 2020, 2020, 1-7.	0.2	3
71	Two cases of recurrent uterine cervical cancer with arterio-enteric fistula treated by femoro-femoral artery bypass in hybrid operation room. <i>International Cancer Conference Journal</i> , 2018, 7, 26-29.	0.2	1
72	Severe fatty liver of pregnancy requiring an extremely large amount of blood transfusion, surgery and transarterial embolization: A case report. <i>Case Reports in Women's Health</i> , 2019, 23, e00130.	0.2	1

#	ARTICLE	IF	CITATIONS
73	From genetic analysis to precision medicine. International Cancer Conference Journal, 2021, 10, 159-159.	0.2	1
74	Increasing our knowledge of germline variants. International Cancer Conference Journal, 2022, 11, 1-1.	0.2	1
75	Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan. International Journal of Clinical Oncology, 2022, , 1.	1.0	1
76	Characterization of patients that can continue conservative treatment for adenomyosis. BMC Women's Health, 2021, 21, 431.	0.8	1
77	Laparoscopic pelvic lymphadenectomy in patients with early-stage endometrial cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2013, 29, 291-296.	0.0	0
78	Various therapeutic effects of immune checkpoint inhibitors. International Cancer Conference Journal, 2020, 9, 169-169.	0.2	0
79	A message from the new editor-in-chief. International Cancer Conference Journal, 2020, 9, 51-51.	0.2	0
80	The perspectives of molecularly targeted therapies which this issue illustrates. International Cancer Conference Journal, 2020, 9, 101-101.	0.2	0
81	A case of left renal atrophy following the development of an infected giant retroperitoneal chylous cyst after laparoscopic para-aortic lymphadenectomy for endometrial cancer. International Cancer Conference Journal, 2020, 9, 203-206.	0.2	0
82	Rare tumor subtypes diagnosed by molecular analysis. International Cancer Conference Journal, 2021, 10, 95.	0.2	0
83	Strategies for the use of immune checkpoint inhibitors. International Cancer Conference Journal, 2021, 10, 265-265.	0.2	0
84	Pitfall in the diagnosis of Lynch syndrome. International Cancer Conference Journal, 2021, 10, 1-1.	0.2	0
85	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015, , .		0